Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

W. F. Anderson, S. Luo, N. Chatterjee, P. S. Rosenberg, R. K. Matsuno, M. T. Goodman, B. Y. Hernandez, M. Reichman, M. P. Dolled-Filhart, R. M. O'Regan, M. Garcia-Closas, C. M. Perou, I. Jatoi, R. W. Cartun, Mark E. Sherman

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: In 2001, the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program established Residual Tissue Repositories (RTR) in the Hawaii, Iowa, and Los Angeles Tumor Registries to collect discarded tissue blocks from pathologic laboratories within their catchment areas. To validate the utility of the RTR for supplementing SEER's central database, we assessed human epidermal growth factor receptor-2 (HER2) and estrogen receptor expression (ER) in a demonstration project. Materials: Using a prepared set of tissue microarrays (TMAs) residing in the Hawaii Tumor Registry (HTR), we performed standard immunohistochemistry. Breast cancers in the TMA were diagnosed in 1995, followed through 2006, and linked to SEER's main database. Results: The TMA included 354 cases, representing 51% of 687 breast cancers in the HTR (1995). The HTR and TMA cases were similar with respect to patient demographics and tumor characteristics. Seventy-six percent (76%, 268 of 354) of TMA cases were HER2+ and/or ER+, i.e., 28 HER2+ER-, 12 HER2+ER+, and 228 HER2-ER+. There were 67 HER2-ER- cases and 19 were unclassified. Age distributions at diagnosis were bimodal with dominant early-onset modes for HER2+ER- tumors and dominant late-onset modes for HER2-ER+ breast cancers. Epidemiologic patterns for concordant HER2+ER+ (double-positive) and HER2-ER- (double-negative) were intermediate to discordant HER2+ER- and HER2-ER+. Conclusion: Results showed contrasting incidence patterns for HER2+ (HER2+ER-) and ER+ (HER2-ER+) breast cancers, diagnosed in 1995. Though sample sizes were small, this demonstration project validates the potential utility of the RTR for supplementing the SEER program.

Original languageEnglish (US)
Pages (from-to)189-196
Number of pages8
JournalBreast Cancer Research and Treatment
Volume113
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

SEER Program
Estrogen Receptors
Registries
Breast Neoplasms
Neoplasms
human ERBB2 protein
Databases
Los Angeles
National Cancer Institute (U.S.)
Age Distribution

Keywords

  • Breast cancer incidence and survival
  • Estrogen receptor (ER)
  • Human epidermal growth factor receptor-2 (HER2)
  • Immunohistochemical stains
  • SEER
  • Tissue microarrays

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program. / Anderson, W. F.; Luo, S.; Chatterjee, N.; Rosenberg, P. S.; Matsuno, R. K.; Goodman, M. T.; Hernandez, B. Y.; Reichman, M.; Dolled-Filhart, M. P.; O'Regan, R. M.; Garcia-Closas, M.; Perou, C. M.; Jatoi, I.; Cartun, R. W.; Sherman, Mark E.

In: Breast Cancer Research and Treatment, Vol. 113, No. 1, 01.2009, p. 189-196.

Research output: Contribution to journalArticle

Anderson, WF, Luo, S, Chatterjee, N, Rosenberg, PS, Matsuno, RK, Goodman, MT, Hernandez, BY, Reichman, M, Dolled-Filhart, MP, O'Regan, RM, Garcia-Closas, M, Perou, CM, Jatoi, I, Cartun, RW & Sherman, ME 2009, 'Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program', Breast Cancer Research and Treatment, vol. 113, no. 1, pp. 189-196. https://doi.org/10.1007/s10549-008-9918-3
Anderson, W. F. ; Luo, S. ; Chatterjee, N. ; Rosenberg, P. S. ; Matsuno, R. K. ; Goodman, M. T. ; Hernandez, B. Y. ; Reichman, M. ; Dolled-Filhart, M. P. ; O'Regan, R. M. ; Garcia-Closas, M. ; Perou, C. M. ; Jatoi, I. ; Cartun, R. W. ; Sherman, Mark E. / Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program. In: Breast Cancer Research and Treatment. 2009 ; Vol. 113, No. 1. pp. 189-196.
@article{79990c0bbb754e9088f1141c7d181ad2,
title = "Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program",
abstract = "Background: In 2001, the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program established Residual Tissue Repositories (RTR) in the Hawaii, Iowa, and Los Angeles Tumor Registries to collect discarded tissue blocks from pathologic laboratories within their catchment areas. To validate the utility of the RTR for supplementing SEER's central database, we assessed human epidermal growth factor receptor-2 (HER2) and estrogen receptor expression (ER) in a demonstration project. Materials: Using a prepared set of tissue microarrays (TMAs) residing in the Hawaii Tumor Registry (HTR), we performed standard immunohistochemistry. Breast cancers in the TMA were diagnosed in 1995, followed through 2006, and linked to SEER's main database. Results: The TMA included 354 cases, representing 51{\%} of 687 breast cancers in the HTR (1995). The HTR and TMA cases were similar with respect to patient demographics and tumor characteristics. Seventy-six percent (76{\%}, 268 of 354) of TMA cases were HER2+ and/or ER+, i.e., 28 HER2+ER-, 12 HER2+ER+, and 228 HER2-ER+. There were 67 HER2-ER- cases and 19 were unclassified. Age distributions at diagnosis were bimodal with dominant early-onset modes for HER2+ER- tumors and dominant late-onset modes for HER2-ER+ breast cancers. Epidemiologic patterns for concordant HER2+ER+ (double-positive) and HER2-ER- (double-negative) were intermediate to discordant HER2+ER- and HER2-ER+. Conclusion: Results showed contrasting incidence patterns for HER2+ (HER2+ER-) and ER+ (HER2-ER+) breast cancers, diagnosed in 1995. Though sample sizes were small, this demonstration project validates the potential utility of the RTR for supplementing the SEER program.",
keywords = "Breast cancer incidence and survival, Estrogen receptor (ER), Human epidermal growth factor receptor-2 (HER2), Immunohistochemical stains, SEER, Tissue microarrays",
author = "Anderson, {W. F.} and S. Luo and N. Chatterjee and Rosenberg, {P. S.} and Matsuno, {R. K.} and Goodman, {M. T.} and Hernandez, {B. Y.} and M. Reichman and Dolled-Filhart, {M. P.} and O'Regan, {R. M.} and M. Garcia-Closas and Perou, {C. M.} and I. Jatoi and Cartun, {R. W.} and Sherman, {Mark E.}",
year = "2009",
month = "1",
doi = "10.1007/s10549-008-9918-3",
language = "English (US)",
volume = "113",
pages = "189--196",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

AU - Anderson, W. F.

AU - Luo, S.

AU - Chatterjee, N.

AU - Rosenberg, P. S.

AU - Matsuno, R. K.

AU - Goodman, M. T.

AU - Hernandez, B. Y.

AU - Reichman, M.

AU - Dolled-Filhart, M. P.

AU - O'Regan, R. M.

AU - Garcia-Closas, M.

AU - Perou, C. M.

AU - Jatoi, I.

AU - Cartun, R. W.

AU - Sherman, Mark E.

PY - 2009/1

Y1 - 2009/1

N2 - Background: In 2001, the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program established Residual Tissue Repositories (RTR) in the Hawaii, Iowa, and Los Angeles Tumor Registries to collect discarded tissue blocks from pathologic laboratories within their catchment areas. To validate the utility of the RTR for supplementing SEER's central database, we assessed human epidermal growth factor receptor-2 (HER2) and estrogen receptor expression (ER) in a demonstration project. Materials: Using a prepared set of tissue microarrays (TMAs) residing in the Hawaii Tumor Registry (HTR), we performed standard immunohistochemistry. Breast cancers in the TMA were diagnosed in 1995, followed through 2006, and linked to SEER's main database. Results: The TMA included 354 cases, representing 51% of 687 breast cancers in the HTR (1995). The HTR and TMA cases were similar with respect to patient demographics and tumor characteristics. Seventy-six percent (76%, 268 of 354) of TMA cases were HER2+ and/or ER+, i.e., 28 HER2+ER-, 12 HER2+ER+, and 228 HER2-ER+. There were 67 HER2-ER- cases and 19 were unclassified. Age distributions at diagnosis were bimodal with dominant early-onset modes for HER2+ER- tumors and dominant late-onset modes for HER2-ER+ breast cancers. Epidemiologic patterns for concordant HER2+ER+ (double-positive) and HER2-ER- (double-negative) were intermediate to discordant HER2+ER- and HER2-ER+. Conclusion: Results showed contrasting incidence patterns for HER2+ (HER2+ER-) and ER+ (HER2-ER+) breast cancers, diagnosed in 1995. Though sample sizes were small, this demonstration project validates the potential utility of the RTR for supplementing the SEER program.

AB - Background: In 2001, the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program established Residual Tissue Repositories (RTR) in the Hawaii, Iowa, and Los Angeles Tumor Registries to collect discarded tissue blocks from pathologic laboratories within their catchment areas. To validate the utility of the RTR for supplementing SEER's central database, we assessed human epidermal growth factor receptor-2 (HER2) and estrogen receptor expression (ER) in a demonstration project. Materials: Using a prepared set of tissue microarrays (TMAs) residing in the Hawaii Tumor Registry (HTR), we performed standard immunohistochemistry. Breast cancers in the TMA were diagnosed in 1995, followed through 2006, and linked to SEER's main database. Results: The TMA included 354 cases, representing 51% of 687 breast cancers in the HTR (1995). The HTR and TMA cases were similar with respect to patient demographics and tumor characteristics. Seventy-six percent (76%, 268 of 354) of TMA cases were HER2+ and/or ER+, i.e., 28 HER2+ER-, 12 HER2+ER+, and 228 HER2-ER+. There were 67 HER2-ER- cases and 19 were unclassified. Age distributions at diagnosis were bimodal with dominant early-onset modes for HER2+ER- tumors and dominant late-onset modes for HER2-ER+ breast cancers. Epidemiologic patterns for concordant HER2+ER+ (double-positive) and HER2-ER- (double-negative) were intermediate to discordant HER2+ER- and HER2-ER+. Conclusion: Results showed contrasting incidence patterns for HER2+ (HER2+ER-) and ER+ (HER2-ER+) breast cancers, diagnosed in 1995. Though sample sizes were small, this demonstration project validates the potential utility of the RTR for supplementing the SEER program.

KW - Breast cancer incidence and survival

KW - Estrogen receptor (ER)

KW - Human epidermal growth factor receptor-2 (HER2)

KW - Immunohistochemical stains

KW - SEER

KW - Tissue microarrays

UR - http://www.scopus.com/inward/record.url?scp=58049209741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58049209741&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-9918-3

DO - 10.1007/s10549-008-9918-3

M3 - Article

C2 - 18256926

AN - SCOPUS:58049209741

VL - 113

SP - 189

EP - 196

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -